NAŁÓG PALENIA PAPIEROSÓW KLASYCZNYCH I ELEKTRONICZNYCH A RYZYKO SKUTECZNEJ FARMAKOTERAPII

Paulina Brewczyńska; Justyna Makowska; Dorota Skrajnowska; Marta Teryks; Andrzej Tokarz

doi:10.56782/pps.110

Published : 2015-04-14

Vol. 13 No. 3 (2015)

ADDICTION TO CONVENTIONAL AND ELECTRONIC CIGARETTES AND THE RISKS OF PHARMACOTHERAPY IN SMOKERS.

Paulina Brewczyńska

Justyna Makowska

Dorota Skrajnowska

Marta Teryks

Andrzej Tokarz

DOI: https://doi.org/10.56782/pps.110

Abstract

Tobacco smoking is associated with multiple drug interactions. Polycyclic aromatic hydrocarbons and other components of tobacco smoke can induce enzymes of the hepatic cytochrome P450 system - primarily CYP1A2 but also CYP2A6, CYP2B6 and CYP2D6, which are responsible for metabolizing many different types of drugs. As a consequence of the augmented metabolism of drugs that are substrates of these enzymes, polycyclic aromatic hydrocarbons may decrease the pharmacological effect of drugs. Accelerated metabolism and faster clearance of drugs require higher drug doses to achieve the desired therapeutic effect. When patients cease smoking, the altered levels of enzymes return to their normal values, which may result in toxic drug concentrations if the dose is maintained. Nicotine, a component of tobacco, is highly addictive and causes pharmacodynamic interactions that alter the response to other drugs. An example of such interactions is provided by women who smoke and use oral contraceptives. Electronic cigarettes, also known as e-cigarettes, are devices designed to imitate regular cigarettes and deliver nicotine via inhalation from an external reservoir. They are purported to deliver nicotine without other toxicants. Some distributors of e-cigarettes promote the product as completely free of harmful substances. Currently, there is a lack of sufficient scientific evidence on the absence or presence of toxic chemicals in the vapour generated by e-cigarettes and inhaled by their users. The impact of cigarette smoking needs to be considered in planning and assessing responses to drug therapy. In particular, the risks associated with cigarette smoking should be taken into account in clinical trials of new drugs. Health care professionals should incorporate the effects of smoking into any therapeutic plans.

Keywords:

cigarette smoking, drugs, interactions, e-cigarettes

Most read articles by the same author(s)

Agnieszka Białek, Andrzej Tokarz, DIETARY SOURCES AND BENEFICIAL HEALTH EFFECTS OF CONJUGATED LINOLEIC ACIDS (CLA) , Prospects in Pharmaceutical Sciences: Vol. 7 No. 1 (2009)
Małgorzata Idzikowska, Marta Janczura, Tomasz Lepionka, Michał Madej, Edyta Mościcka, Justyna Pyzik, Paulina Siwek, Weronika Szubierajska, Dorota Skrajnowska, Andrzej Tokarz, NANOTECHNOLOGY IN FOOD PRODUCTION – DEVELOPMENT, RISKS AND REGULATORY ASPECTS , Prospects in Pharmaceutical Sciences: Vol. 10 No. 4 (2012)
Katarzyna Czuba, Magdalena Mazurkiewicz, Kamil Kamiński, Filip Różewski, Dorota Skrajnowska, Andrzej Tokarz, BIOTERRORISM – THREAT, PREVENTIVE ACTIONS, INTERNATIONAL LAW , Prospects in Pharmaceutical Sciences: Vol. 9 No. 2 (2011)
Andrzej Tokarz, Małgorzata Jelińska, Agnieszka Ozga, ISOPROSTANES - NEW BIOMARKERS IN LIPID PEROXIDATION IN VIVO , Prospects in Pharmaceutical Sciences: Vol. 2 No. 2 (2004)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Brewczyńska, P., Makowska, J., Skrajnowska, D., Teryks, M., & Tokarz, A. (2015). ADDICTION TO CONVENTIONAL AND ELECTRONIC CIGARETTES AND THE RISKS OF PHARMACOTHERAPY IN SMOKERS. Prospects in Pharmaceutical Sciences, 13(3), 13–20. https://doi.org/10.56782/pps.110

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Kroon L.A. Drug interactions with smoking. Am. J. Health-Syst. Pharm. 2007, 64 (18), 1917-1921. DOI: https://doi.org/10.2146/ajhp060414

Zevin S., Benowitz N.L. Drug interactions with tobacco smoking: an update. Clin. Pharmacokinetic. 1999, 36, 425-438. DOI: https://doi.org/10.2165/00003088-199936060-00004

Kroon L.A. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit. Care Nurs. Clin. North Am. 2006, 18, 53-62. DOI: https://doi.org/10.1016/j.ccell.2005.11.007

Schaffer S.D., Yoon S., Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J. Clin. Nurs. 2009, 18(11), 1533-1540. DOI: https://doi.org/10.1111/j.1365-2702.2008.02724.x

Stańczak A., Lewgowd W. Interakcje leków ze składnikami dymu tytoniowego Cz. II. Brom. Chem. Toksykol. 2009, XLII (1), 97-103.

Stańczak A., Lewgowd W. Interakcje leków ze składnikami dymu tytoniowego Cz. I. Brom. Chem. Toksykol. 2008, XLI (4), 1030-1036.

Mańka M. Niepożądane reakcje lekowe u palaczy tytoniu. Puls Medycyny. 2012, 14(253) (www.kodekswalkizrakiem.pl/ download/pdf/20121022_Puls_Medycyny.pdf)

Fankhauser M. Drug interactions with tobacco smoke: implications for patient care. Current Psychiatry, 2013, 12(1), 12-16.

Komunikat z badań BS/107/2012; Postawy wobec palenia papierosów CBOS, Warszawa, sierpień 2012 (www.cbos.pl/ SPISKOM.POL/2012/K_107_12.PDF)

Raport z ogólnopolskiego badania ankietowego na temat postaw wobec palenia tytoniu (pssekoszalin.pis.gov.pl/plikijednostki/ .../file/.../GiS_Raport_2013.pdf)

Seńczuk W. Toksykologia Współczesna, PZWL, Warszawa, 2005

Faber M.S., Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther, 2004, 76(2),178-184. DOI: https://doi.org/10.1016/j.clpt.2004.04.003

McKinnon R.A, Evans A.M. Cytochrome P450. Clinically Significant Drug Interactions. Aust. J Hosp Pharm., 2000, 30, 146. DOI: https://doi.org/10.1002/jppr2000304146

Ambrosone C.B. Freudenheim J.L. Graham S., Marshall J.R., Vena J.E., Brasure J.R., Laughlin R, Nemoto T., Michalek A.M., Harrington A. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res, 1995, 55(16), 3483-3485.

Moon Y.J. Wang X., Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. in Vitro. 2006, 20(2), 187-210. DOI: https://doi.org/10.1016/j.tiv.2005.06.048

Stockley’s, Drug Interactions. A source book of interactions, their mechanisms, clinical importance and management. 2008, The Pharmaceutical Press, London, Eight Edition. Edited by Karen Baxter (www. stockley-drug-interaction-2008.pdf)

Mayo P.R. Effect of passive smoking on theophylline clearance in children. The Drug Monit. 2001, 23(5), 503-505. DOI: https://doi.org/10.1097/00007691-200110000-00001

Orzechowska-Juzwenko K. Farmakologia kliniczna. Znaczenie w praktyce medycznej, Górnicki Wydawnictwo Medyczne, Wrocław, 2006.

Hukkanen J., Jakob P 3rd, Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005, 57(1), 79-115. DOI: https://doi.org/10.1124/pr.57.1.3

Perkins K.A., Lerman C., Keenan J., Fonte C., Coddington S. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers. Nicotine Tob. Res. 2004, 6(3), 501-507. DOI: https://doi.org/10.1080/14622200410001696547

Kostka-Trąbka E., Woroń J. Interakcje leków w praktyce klinicznej. PZWL Warszawa 2011 (Wydanie II uaktualnione).

Eldon M.A., Luecker P.W., MacGee J., Ritschel W.A. Lack of effect withdrawal from cigarette smoking on theophyline pharmacokinetics. J. Clin. Pharmacol., 1987, 27(3), 221-225. DOI: https://doi.org/10.1002/j.1552-4604.1987.tb02189.x

Gex-Fabry M., Balant-Gorgia A.E., Balant L.P. Therapeuting drug monitoring of olanzapine: the combined effect of age, gender, smoking and comedication. Ther. Drug Monit. 2003, 25(1), 46-53. DOI: https://doi.org/10.1097/00007691-200302000-00007

Diaz F.J., de Leon J., Josiassen R.C., Cooper T.B., Simpson G.M. Plasma clozapine concentration coefficients of variation in long-term study. Schizophr Res. 2005, 72(2-3), 131-135. DOI: https://doi.org/10.1016/j.schres.2004.03.017

Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patient with schizophrenia. J. Clin. Psychopharmacol, 2001, 21(4), 398-407. DOI: https://doi.org/10.1097/00004714-200108000-00007

Haring C., Meise U., Humpel C, Saria A., Fleischhacker W.W., Hinterhuber H. Dose-related plasma levels of clozapine; influence of smoking, behaviour sex and age. Psychopharmacology. 1989, 99 (supl.), 38-40. DOI: https://doi.org/10.1007/BF00442557

Carrillo J.A., Herraiz A.G., Ramos S.I., Gervasini G., Vizcaino S., Benitez J. Role of smoking – induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady- state concentration of olanzepine. J. Clin. Psychopharmacol. 2003, 23(2), 119-27. DOI: https://doi.org/10.1097/00004714-200304000-00003

B. Fulton, K.L. Goa, Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs, 1997, 53(2), 281-98. DOI: https://doi.org/10.2165/00003495-199753020-00007

de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr. Serv. 2004, 55(5), 491-3. DOI: https://doi.org/10.1176/appi.ps.55.5.491

Nemeroff C.B., Kinkead B., Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J. Clin. Psychiatry. 2002, 63, 13, 5-11.

Smoking and drug interactions 2007, Medicines Information Centre Pharmacy Department, UK Medicines Information, prepared by The Medicines Information Team, Pharmacy Department, Mersey Care NHS Trust (www.merseycare.nhs.uk/Library/.../Smoking_ Interactions.pdf)

Schein J.R. Cigarette smoking and clinically significant drug interactions. Ann. Pharmacother. 1995, 29 (11), 1139-48. DOI: https://doi.org/10.1177/106002809502901113

Wittkowsky A.K. Drug interactions update: drugs, herbs, and oral anticoagulation. J. Thromb. Thrombolysis. 2001,12(1), 67 –71. DOI: https://doi.org/10.1023/A:1012742628628

Himmelmann A., Jendle J., Mellen A., Petersen A.H., Dahl U.L., Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care, 2003, 26(3), 677-82. DOI: https://doi.org/10.2337/diacare.26.3.677

Wang. Z., Hall S.D., Maya J.F., Asghar A., Gorski J.C. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br. J. Clin. Pharmacol. 2003, 55, 77 - 85. DOI: https://doi.org/10.1046/j.1365-2125.2003.01731.x

Bol J., Mathijssen R.H.J., Loos W.J., Friberg LE., Schaik R.H.N., de Jonge MJ.A., Planting A.S.Th., Verweij J., Sparreboom A., de Jong F.A. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Onc. 2007, 25(19), 2719-26. DOI: https://doi.org/10.1200/JCO.2006.09.6115

Burkman R., Schlesselman J.J., Zieman M. Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004.190(4), S5-22. DOI: https://doi.org/10.1016/j.ajog.2004.01.061

Seibert C., Barbouche E., Fagan J., Myint E., Wetterneck T., Wittemyer M. Prescribing oral contraceptives for women older than 35 years of age. Ann. Intern. Med. 2003;138(1):54-64. DOI: https://doi.org/10.7326/0003-4819-138-1-200301070-00013

Schiff I., Bell W.R., Davis V., Kessler C.M., Meyers C., Nakajima S., Sexton B.J. Oral contraceptives and smoking, current considerations: recommendations of a consensus panel. Am. J. Obstet. Gynecol, 1999, 180(6), S383-384. DOI: https://doi.org/10.1016/S0002-9378(99)70700-3

World Health Organization. Low dose combined oral contraceptives. In: Medical eligibility criteria for contraceptive use. 3rd edition. Geneva (Switzerland). 7 World Health Organization; 2004., 1-24. (http://www.who.int/reproductive-health/ publications/ mec/mec.pdf.)

Heinemann L.A., Assmann A., DoMinh T., Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational study on Oral Contraceptives and Health of Young Woman. Eur. J. Contracept Reprod. Health Care. 1999, 4(2), 67-73. DOI: https://doi.org/10.3109/13625189909064007

Chalmers G.W., MacLeod K.J., Little S.A., Thomson L.J., McSharry C.P., Thomson N.C. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax, 2002, 57(3), 226-230. DOI: https://doi.org/10.1136/thorax.57.3.226

Chaudhuri R., Livingston E., McMahon A.D., Thomson L., Borland W., Thomson N.C. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003, 168(11),1308-1311. DOI: https://doi.org/10.1164/rccm.200304-503OC

Thomson N.C., Spears M. The influence of smoking on the treatment response in patients with asthma. Curr. Opin. Allergy Clin. Immunol. 2005, 5(1),57-63. DOI: https://doi.org/10.1097/00130832-200502000-00011

Tomlinson J.E., McMahon A.D., Chaudhuri R., Thompson J.M., Wood S.F., Thomson N.C. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax, 2005, 60, 282-287. DOI: https://doi.org/10.1136/thx.2004.033688

Etter J.F., Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011,106 (11), 2017-2028. DOI: https://doi.org/10.1111/j.1360-0443.2011.03505.x

Goniewicz M.Ł., Knysak J., Gawron M., Kosmider L.,. Sobczak A., Kurek J., Prokopowicz A., Jablonska-Czapla M.,. Rosik-Dulewska C, Havel Ch., Benowitz Jacop P., Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes, Tob. Control, 2013, 0, 1-7. DOI: https://doi.org/10.1136/tobaccocontrol-2012-050859

Vardavas C.I., Anagnostopoulos N., Kougias M., Evangelopoulou V., Connolly G.N., Behrakis P.K. Short-term pulmonary effects of using an electronic cigarette. Chest. 2012, 141, 1400–1406. E-Cigarette Laws Worldwide. (www.ecigarette-politics.com/ electronic-cigarettes-global-legal-status.html) DOI: https://doi.org/10.1378/chest.11-2443

Dyrektywa Parlamentu Europejskiego i Rady 2014/40/UE z dnia 3 kwietnia 2014 r. w sprawie zbliżenia przepisów ustawowych, wykonawczych i administracyjnych państw członkowskich w sprawie produkcji, prezentowania i sprzedaży wyrobów tytoniowych i powiązanych wyrobów oraz uchylająca dyrektywę 2001/37/WE (www.polbi.pl/pl/eurlex.spr?id=1705650)

Paulina Brewczyńska

Affiliation:

Studenckie Koło Naukowe „Bromatos” przy Zakładzie Bromatologii Poland

Justyna Makowska

Affiliation:

Studenckie Koło Naukowe „Bromatos” przy Zakładzie Bromatologii Poland

Dorota Skrajnowska

Affiliation:

Zakład Bromatologii, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny Poland

Marta Teryks

Affiliation:

Studenckie Koło Naukowe „Bromatos” przy Zakładzie Bromatologii Poland

Andrzej Tokarz

Affiliation:

Studenckie Koło Naukowe „Bromatos” przy Zakładzie Bromatologii Poland